Glutamine Cap/Tab

PreclinicalSmall molecule

HHams Hamed Abdelrahman

Glutamine Cap/Tab is one of 21 small molecule programs targeting Lichen Planus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lichen PlanusActive, not recruiting

Lichen PlanusPreclinical

Active, not recruiting

Competition

Competitive Landscape

29 competitors in Lichen Planus

#DrugCompanyPhaseTrials

Plaquenil

Alnylam Pharmaceuticals

Approved

—2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—3

Elidel

BBausch Health Americas, Inc.

Approved

—4

Decadron

AAspen Global Incorporated

Otezla

2 6

Jakafi

Incyte

Phase 2

1 7

Olumiant

Eli Lilly

Phase 2

1 8

Trexall

Alnylam Pharmaceuticals

Phase 2

1 9

Cosentyx

Novartis

Phase 2

1 10

Soriatane

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lichen Planus1 trial

Glutamine With Topical Corticosteroids for Lichen Planus Treatment

Completed·HHams Hamed Abdelrahman·N/A·NCT04442633·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Glutamine Cap/Tab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glutamine Cap/Tab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glutamine Cap/Tab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hams Hamed Abdelrahman company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHams Hamed Abdelrahman

Glutamine Cap/Tab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lichen Planus1 trial

References

Drug Info

Quick Facts

Related News